This is a randomized, double-blind, placebo-controlled study with an OLE.~Participants will be randomized to receive namilumab or placebo in the 26-week Double-blind Treatment Period of the study. Namilumab, or placebo, will be administered subcutaneously (SC) every 4 weeks through Week 22 after the initial dosing period.~All participants, who complete the 26-week Double-blind Treatment Period, may be eligible to participate in the 28-week OLE.~Further details are in the protocol.
This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).